Hydrochlorothiazid-13C,d2

• UNSPSC Description:

  Hydrochlorothiazid-13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect[1][2][3].

• Target Antigen:

  Isotope-Labeled Compounds; Potassium Channel; TGF-beta/Smad

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Membrane Transporter/Ion Channel;Others;Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Cardiovascular Disease

• Purity:

  98.64

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S1(C2=CC(S(N)(=O)=O)=C(Cl)C=C2N[13C]([2H])([2H])N1)=O

• Molecular Weight:

  300.74

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Duarte, J.D. and R.M. Cooper-DeHoff, Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther, 2010. 8(6): p. 793-802.|[3]Jinghong Luo, et al. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. Cardiovasc Ther. 2017 Apr;35(2).|[4]Magdy M Abdelquader, et al. Inhibition of Co-Crystallization of Olmesartan Medoxomil and Hydrochlorothiazide for Enhanced Dissolution Rate in Their Fixed Dose Combination. AAPS PharmSciTech. 2018 Dec 17;20(1):3.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1190006-03-1